Overview Dividends

(PETS) PetMed Express - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7163821066

Prescription,Medications,Non-Prescription,Supplies,Flea,Control,Treats

Other Specialty Retail
Market Cap in USD: 74m

IPO / Inception: 1999-04-26
Return 12m vs S&P 500: -43.2%

EPS (Earnings per Share)

EPS CAGR: -66.14%
EPS Trend: -64.2%

Last SUE: -2.62
Qual. Beats: 0

Revenue

Rev. CAGR: -10.55%
Rev. Trend: -57.8%

Last SUE: 4.00
Qual. Beats: 1

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	65.9%
Value at Risk 5%th	88.4%
Relative Tail Risk	-18.42%

Reward TTM
Sharpe Ratio	0.02
Alpha	-46.68
CAGR/Max DD	-0.44

Character TTM
Hurst Exponent	0.502
Beta	1.059
Beta Downside	1.249

Drawdowns 3y
Max DD	92.37%
Mean DD	65.99%
Median DD	77.86%

Description: PETS PetMed Express May 19, 2025

PetMed Express Inc (NASDAQ:PETS) is a US-based pet pharmacy that offers a wide range of products for dogs, cats, and horses, including prescription and non-prescription medications, health products, and supplies. The companys product portfolio encompasses flea and tick control, bone and joint care, vitamins, nutritional supplements, and specialty medications, as well as pet food, beds, crates, and other supplies. With a strong online presence, PetMed Express sells its products through its website, mobile app, customer support center, and direct mail/print marketing campaigns.

As a leading online pet pharmacy, PetMed Express has established a competitive advantage through its diversified product offerings, user-friendly digital platforms, and customer-centric services. The companys ability to provide affordable and convenient access to a broad range of pet healthcare products has contributed to its growth and customer loyalty. With a market capitalization of $74.78M USD, PetMed Express operates in the highly competitive pet specialty retail industry, where it competes with other online retailers, brick-and-mortar pet stores, and veterinary clinics.

Analyzing the and of PetMed Express, we can identify some key trends and insights. The stocks recent price movement indicates a potential bullish trend, as the short-term moving averages (SMA20 and SMA50) are above the current price, while the long-term moving average (SMA200) is higher, suggesting a potential resistance level. The Average True Range (ATR) indicates a relatively moderate level of volatility. From a fundamental perspective, the companys high P/E ratio and forward P/E ratio suggest that investors have high expectations for future earnings growth.

Based on the available data, a forecast for PetMed Express can be constructed. Given the companys strong online presence, diversified product portfolio, and competitive advantages, we can expect continued growth in sales and earnings. The recent price movement and technical indicators suggest a potential short-term upside, with a target price of $4.20-$4.50 in the next few weeks. However, the high P/E ratio and forward P/E ratio indicate that the stock may be sensitive to earnings surprises, and any disappointment could lead to a price correction. Therefore, a buy recommendation is given with a moderate risk profile, and a stop-loss level around $3.50.

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income (-41.1m TTM) > 0 and > 6% of Revenue (6% = 12.5m TTM)

FCFTA -0.32 (>2.0%) and ΔFCFTA -26.51pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 1.33% (prev 7.14%; Δ -5.80pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.27 (>3.0%) and CFO -27.5m > Net Income -41.1m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 1.05 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (20.9m) change vs 12m ago -0.25% (target <= -2.0% for YES)

Gross Margin 28.37% (prev 26.03%; Δ 2.34pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 164.5% (prev 177.3%; Δ -12.81pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -24.79 (EBITDA TTM -2.56m / Interest Expense TTM 326.0k) >= 6 (WARN >= 3)

Altman Z'' 0.97

(A) 0.03 = (Total Current Assets 59.5m - Total Current Liabilities 56.7m) / Total Assets 100.3m

(B) 0.24 = Retained Earnings (Balance) 23.9m / Total Assets 100.3m

(D) 0.42 = Book Value of Equity 23.9m / Total Liabilities 57.2m

Total Rating: 0.97 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 14.12

1. Piotroski 2.50pt

2. FCF Yield -83.37%

3. FCF Margin -15.55%

4. Debt/Equity 0.02

5. Debt/Ebitda 13.81

6. ROIC - WACC (= -21.52)%

7. RoE -57.17%

8. Rev. Trend -57.80%

9. EPS Trend -64.22%

What is the price of PETS shares?

As of December 27, 2025, the stock is trading at USD 3.47 with a total of 119,888 shares traded.
Over the past week, the price has changed by -3.61%, over one month by +96.05%, over three months by +30.94% and over the past year by -34.03%.

Is PETS a buy, sell or hold?

PetMed Express has received a consensus analysts rating of 2.00. Therefor, it is recommend to sell PETS.

Strong Buy: 0
Buy: 0
Hold: 1
Sell: 0
Strong Sell: 1

What are the forecasts/targets for the PETS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	2.8	-20.7%
Analysts Target Price	2.8	-20.7%
ValueRay Target Price	2.2	-38%

PETS Fundamental Data Overview December 27, 2025

Market Cap USD = 74.2m (74.2m USD * 1.0 USD.USD)
P/E Forward = 17.9211
P/S = 0.374
P/B = 1.762
P/EG = 2.58
Beta = 0.767
Revenue TTM = 208.1m USD
EBIT TTM = -8.08m USD
EBITDA TTM = -2.56m USD
Long Term Debt = 768.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 477.0k USD (from shortTermDebt, last quarter)
Debt = 768.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -35.3m USD (from netDebt column, last quarter)
Enterprise Value = 38.8m USD (74.2m + Debt 768.0k - CCE 36.1m)
Interest Coverage Ratio = -24.79 (Ebit TTM -8.08m / Interest Expense TTM 326.0k)
FCF Yield = -83.37% (FCF TTM -32.4m / Enterprise Value 38.8m)
FCF Margin = -15.55% (FCF TTM -32.4m / Revenue TTM 208.1m)
Net Margin = -19.73% (Net Income TTM -41.1m / Revenue TTM 208.1m)
Gross Margin = 28.37% ((Revenue TTM 208.1m - Cost of Revenue TTM 149.1m) / Revenue TTM)
Gross Margin QoQ = 27.98% (prev 28.14%)
Tobins Q-Ratio = 0.39 (Enterprise Value 38.8m / Total Assets 100.3m)
Interest Expense / Debt = 42.45% (Interest Expense 326.0k / Debt 768.0k)
Taxrate = -0.11% (negative due to tax credits) (9000 / -8.51m)
NOPAT = -8.09m (EBIT -8.08m * (1 - -0.11%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 1.05 (Total Current Assets 59.5m / Total Current Liabilities 56.7m)
Debt / Equity = 0.02 (Debt 768.0k / totalStockholderEquity, last quarter 43.1m)
Debt / EBITDA = 13.81 (negative EBITDA) (Net Debt -35.3m / EBITDA -2.56m)
Debt / FCF = 1.09 (negative FCF - burning cash) (Net Debt -35.3m / FCF TTM -32.4m)
Total Stockholder Equity = 71.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -40.93% (Net Income -41.1m / Total Assets 100.3m)
RoE = -57.17% (Net Income TTM -41.1m / Total Stockholder Equity 71.8m)
RoCE = -11.13% (EBIT -8.08m / Capital Employed (Equity 71.8m + L.T.Debt 768.0k))
RoIC = -11.27% (negative operating profit) (NOPAT -8.09m / Invested Capital 71.8m)
WACC = 10.25% (E(74.2m)/V(74.9m) * Re(9.92%) + D(768.0k)/V(74.9m) * Rd(42.45%) * (1-Tc(-0.00)))
Discount Rate = 9.92% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.64%
Fair Price DCF = unknown (Cash Flow -32.4m)
EPS Correlation: -64.22 | EPS CAGR: -66.14% | SUE: -2.62 | # QB: 0
Revenue Correlation: -57.80 | Revenue CAGR: -10.55% | SUE: 4.0 | # QB: 1
EPS current Year (2026-03-31): EPS=-0.22 | Chg30d=-0.100 | Revisions Net=-1 | Growth EPS=+26.7% | Growth Revenue=-12.3%
EPS next Year (2027-03-31): EPS=0.01 | Chg30d=+0.090 | Revisions Net=+1 | Growth EPS=+104.6% | Growth Revenue=+3.0%

Additional Sources for PETS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle